Opioid partial agonist

This page covers all Opioid partial agonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Mu-opioid receptor (μ-OR), Opioid receptors, mu-opioid receptor.

Targets

Mu-opioid receptor (μ-OR) · Opioid receptors · mu-opioid receptor

Marketed (1)

• Higher bioavailability BNX sublingual tablets · Orexo AB · Pain management; Opioid use disorder
  BNX is a buprenorphine formulation designed to provide higher bioavailability through sublingual administration, enhancing opioid receptor partial agonism for pain and opioid use disorder treatment.

Phase 3 pipeline (4)

• Placebo First, then ORADUR® · Orient Pharma Co., Ltd. · Pain management
  ORADUR is a sustained-release formulation of buprenorphine.
• pre-implementation baseline including opioid · Brigham and Women's Hospital · Addiction
  Buprenorphine is a partial opioid agonist that works by activating opioid receptors in the brain, reducing the craving for opioids and alleviating withdrawal symptoms.
• Standard Buprenorphine Dose · Rutgers, The State University of New Jersey · Pain management
  Buprenorphine acts as a partial agonist at the mu-opioid receptor, providing pain relief and reducing withdrawal symptoms.
• Sublingual buprenorphine-naloxone · Yih-Ing Hser · Pain
  Buprenorphine is a partial opioid agonist that binds to opioid receptors, while naloxone is an opioid antagonist that blocks opioid receptors.